A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
Status:
Withdrawn
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I study (an early study to check the safety of a new drug or drug
combination) to find the safest and most tolerated dose of the combination of oxaliplatin
with gemcitabine and MEK 162 in patients with biliary cancer (including gallbladder cancers
and cancers associated with the bile ducts leading from the gallbladder and to and from the
liver) that is not curable by surgery and/or has spread beyond the biliary tree (place where
cancer started). Everyone will receive the same standard doses of oxaliplatin and gemcitabine
but may receive different doses of MEK 162.
MEK 162 is a new drug which plays an important role in the regulation of cell growth and has
been shown to shrink tumours in patients with biliary cancer and other types of human
cancers. This type of drug has also been shown to shrink tumours when given in combination
with cisplatin and gemcitabine in research studies done in animals and in some patients with
biliary cancer.